Use of ED and hospital services for patients with acute leukemia after induction therapy: One year follow-up by Bryant, Ashley Leak et al.
Use of ED and Hospital Services for Patients with Acute 
Leukemia after Induction Therapy: One year Follow-Up
Ashley Leak Bryant, PhD, RN-BC, OCN [Assistant Professor],
School of Nursing, The University of North Carolina at Chapel Hill, Office: 919-966-5329, Fax: 
919-843-9900, anleak@email.unc.edu
Allison M. Deal, MS [Biostatistician],
Lineberger Comprehensive Cancer Center Biostatistics Core, The University of North Carolina at 
Chapel Hill, Allison_Deal@med.unc.edu
AnnMarie Walton, RN, MPH, OCN, CHES [Doctoral Candidate],
University of Utah College of Nursing, Social Clinical Research Specialist, Lineberger 
Comprehensive Cancer Center, Adjunct Clinical Instructor, School of Nursing, The University of 
North Carolina at Chapel Hill, annmarie.walton@utah.edu, awalton@unch.unc.edu
William Wood, MD, MPH [Assistant Professor of Medicine],
Division of Hematology/Oncology, The University of North Carolina at Chapel Hill, 
wawood@med.unc.edu
Hyman Muss, MD [Professor of Medicine], and
Division of Hematology/Oncology, The University of North Carolina at Chapel Hill, 
Hyman_muss@med.unc.edu
Deborah K. Mayer, PhD, RN, AOCN, FAAN [Professor]
School of Nursing, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 
dmayer@unc.edu
Abstract
Previous studies have documented use of health care services by oncology patients in the 
Emergency Department (ED), but little is known about the utilization of health services of patients 
with acute leukemia after induction therapy. The aim of this study was to examine chief reasons 
for ED and hospital use by patients newly diagnosed with acute leukemia patients after induction 
therapy up to one year after discharge. A retrospective, longitudinal study of all visits to the ED or 
unplanned hospital admissions at a single institution for patients with acute leukemia was 
conducted. Inclusion criteria were patients ≥18 years of age at time of diagnosis, a confirmed 
diagnosis of AML or ALL, and received and discharged from induction treatment between 2007–
2010. Donabedian’s structure-process-outcome framework guided this study examining health 
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services utilization and assessing patient outcomes. 80 patients met the inclusion criteria; 52 had 
AML and 28 had ALL; median age was 48 (range: 18–76) and 29% (n=23) were non-Caucasian. 
70% (n=56) were discharged from induction in remission. 81% (n=65) had at least 1 ED or 
hospitalization event, and 44% (n=35) had 2 or more events. Of 137 events in 65 patients, the most 
common reason was neutropenic fever/infection (55%), bleeding (12%), and GI problems (11%). 
Mean number of events for ALL was 2.43 compared to 1.33 for AML patients (p=0.02), and 2.23 
for <50 years of age compared to 1.20 for those older (p=0.002). 20 patients died within one year 
of diagnosis. Findings from this study can help inform health services delivery and utilization 
among patients with acute leukemia after induction therapy. Oncology providers can anticipate 
discharge needs and enhance follow-up care for those at higher risk for problems needing 
hospitalization.
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Introduction
Emergency Departments (EDs) are coping with the increasing symptom needs of patients 
with cancer. These symptoms may be a life threatening complication requiring further 
evaluation and treatment, and even hospitalization. Visiting the ED may be appropriate to 
manage acute cancer related problems such as fever, pain or respiratory distress and do not 
necessarily represent inappropriate cancer care management or limited community services 
(Mayer et al, 2011; Vandyk et al, 2012). However, EDs with large volumes of patients and 
with overcrowding may not be the best environments for cancer patients with neutropenia. 
Neutropenia increases their risk of developing other bacterial, viral, and fungal infections.
There are few studies available on ED and hospital use by oncology patients. Bozdemir et al 
(2009) studied all visits to the ED by patients with cancer at one institution in Turkey over a 
6 month period and documented 324 visits by 245 patients. Nearly 40% of those patients 
had more than one visit with pain, nausea and vomiting as two common symptoms. Almost 
half of those 245 patients died within three months of their ED visit. Mayer, et al (2011) 
conducted a population-based cross sectional evaluation of 37,760 cancer-related ED visits 
in North Carolina in 2008 utilizing the North Carolina Disease Event Tracking and 
Epidemiologic Collection Tool (NC DETECT) (Hackenwerth et al, 2009). The most 
common chief complaints were related to pain, respiratory distress, and gastrointestinal (GI) 
distress. Of all cancer types, the patients most likely to present to the ED were lung cancer 
patients; a total of 63.2% of visits resulted in hospital admittance compared to 15.1% for 
non-cancer related visits.
Additional analyses found that of the 37,760 cancer-related ED visits, 283 patients died in 
the ED with common presenting reasons including shortness of breath and GI complaints 
(Leak et al, 2012). An earlier study examined cancer deaths in Canada and found that 83.8% 
of those who died had visited the ED during their last 6 months of life (Barbera, 2010). The 
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presenting symptoms were similar to Leak et al, 2012 including abdominal pain, dyspnea, 
pneumonia, and fatigue.
Not only do patients enter the ED for treatment or disease related symptoms, they may also 
be admitted to the hospital for further assessment and management. In 2009, there were 4.7 
million cancer-related hospitalizations among adults, and 1.2 million had identified cancer 
as the chief diagnosis (Anhang, 2012). The mean length of stay for leukemia related 
hospitalizations (e.g. re-admissions for symptom management) was 15.5 days, with a mean 
cost per stay at $40,200 (Anhang, 2012). Patients with leukemia had the most expensive 
cancer hospitalizations compared to all other cancers in 2009. Patients with acute leukemia 
can become acutely ill within the course of their first treatment, and it is important that we 
understand their utilization of the ED and hospital after induction therapy so we may best 
coordinate efforts to prevent or anticipate their needs.
Aims
The aims of this study were to 1) describe chief reasons for ED and hospital use by newly 
diagnosed acute leukemia patients after induction therapy through one year after discharge 
and 2) to explore the sociodemographic and disease characteristics of those who utilized the 
ED or were hospitalized. Donabedian’s structure-process-outcome framework guided this 
study by examining health services utilization and assessing patient outcomes (Donabedian, 
2005). Structure is the setting for which care is provided and delivered (ED or hospital), 
process is when the patient seeks and follows through with care provided at either the ED, 
hospital, or both, and outcome is the number of events to the ED and hospital.
Materials and Methods
Patients were identified from the Carolina Data Warehouse for Health (CDW-H), a central 
repository including clinical, research and administrative data for patients receiving services 
at the University of North Carolina Hospitals (UNC). The warehouse contains data from 
various clinical and operations systems within the UNC Health Care System. This 
enterprise-wide data warehouse was developed in 2004 to meet the dual challenges of 
enhancement of quality of care and clinical research with our patient populations. The study 
was reviewed and approved by the University of North Carolina Institutional Review Board.
The CDW-H was queried for all patients who received services at UNC from 2007–2010 
with an ICD9 code of leukemia (208.00; 208.01; 208.2; 205.0; 205.01; 205.02; 204.00; 
204.01; 204.02; 206.00; 206.01; 206.02). The medical records of 463 patients were then 
reviewed for possible inclusion. Eligible patients were ≥18 years of age at the time of 
diagnosis, had a confirmed diagnosis of AML or ALL, and received and were discharged 
from induction treatment at the University of North Carolina Cancer Hospital. Data from 
2004 to 2007 are not complete; hence we restricted our sample to those patients diagnosed 
with acute leukemia in or after 2007. We further narrowed our sample by excluding patients 
diagnosed before 2007 (n=155) or in childhood (n=24), diagnosed at an outside facility 
(n=63), with leukemia other than AML or ALL (n=40), leukemia secondary to 
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myelodysplasia or other malignancies (n=46), secondary cancer (n=46), insufficient clinical 
documentation (n=6), or died before discharge (n=3). (Figure 1).
Data were collected on the 80 eligible patients including demographic/clinical 
characteristics and for each ED visit and hospitalization after initial induction therapy using 
the patient’s electronic medical record and searching under both ED Notes (capturing all ED 
visits) and History and Physical Notes (capturing all hospital admissions). An event is 
defined as one of the three following occurrences: ED only (the patient came to the ED and 
was discharged from the ED, hospital only (the patient was admitted directly to the hospital), 
or ED to hospital (the patient came to the ED and was admitted to the hospital). We were 
assured that the patients with no events included in this analysis truly had no events outside 
our institution since there were other notes in their charts indicating continued contact 
throughout the year with UNC physicians.
Descriptive statistics are provided, including medians and ranges. Differences between 
patients were compared using Fisher’s Exact tests for categorical variables and Wilcoxon 
Rank Sum tests for continuous variables. Linear regression was used to model the outcome 
of number of events, and Cox proportional hazards models were used to model the outcome 
of time to first event. Patients who died without an event in the first year were censored at 
time of death (n=2). Patients with no events during the first year were censored at 365 days 
(n=13). Univariable and multivariable models were used for both ED visit and 
hospitalization, covariates included in the multivariable models included age, minority, 
insurance, disease type, and remission. All analyses were conducted using SAS statistical 
software v9.3 (Cary, NC).
Results
Sample
This retrospective longitudinal study included 80 patients ≥18 years of age at time of 
diagnosis with a confirmed diagnosis of AML or ALL who received and were discharged 
from induction treatment at the North Carolina Cancer Hospital between 2007–2010 [Table 
1]. Patient data for one year after discharge from initial diagnosis and treatment 
hospitalization were reviewed for occurrence of emergency department visits and 
hospitalizations. The sample (n=80) was comprised of 44 females and 36 males (median age 
48, range 18–76,). There were 29% (n=23) non-Whites (14 African American/Black, 5 
Hispanic, 3 American Indian, 1 Asian) with African Americans comprising 17% of the 
sample. The majority of patients were married/partnered (72%) and 54% had public 
insurance [Table 1]. About two-thirds of patients (65%) had AML and 35% had ALL. Most 
demographic variables were similar between the two groups, however, the patients with 
AML were significantly older (median age 54 v 39, p=0.01) and less likely to be minorities 
(20% v 46%, p=0.02). Diagnosis year was evenly distributed across the four years and the 
most common leukemia subtype for AML was M2 (34%). According to the French-
American-British classification of AML, M2, known as acute myeloblastic leukemia with 
maturation, has a favorable prognostic outcome (ACS, 2014b). Most patients (70%) were in 
remission after induction treatment.
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ED visits and Hospitalization—Overall, 81% (n=65) of patients had at least one 
unplanned visit to the ED or hospital within the first year; 93% (n=26) of ALL patients had 
events compared to 75% (n=39) of AML patients (Table 2). Of the 65 patients who had at 
least one ED or hospitalization, 30 (38%) had one event, 14 (18%) had two, and 21 (26%) 
had three or more events. The mean number of events was significantly higher for ALL 
compared to AML patients (2.43 v 1.33, p=0.005). The time to first event was also 
compared between groups and showed that the median time to first event was shorter for the 
ALL compared to AML patients (36.5 days v 115 days, p=0.005).
These 65 patients who had at least one ED or hospitalization had a total of 137 events, 6% of 
which were only to the ED, 34% entering the hospital through the ED, and 60% only to the 
hospital. Chief reasons for use of services were classified into 1 of 10 categories based on 
final discharge diagnoses (Table 3). Categorization of discharge diagnoses was guided by the 
Mayer et al (2011) paper with categories including neutropenic fever, infection, anemia, 
cardiovascular, gastrointestinal, respiratory, pain, thrombocytopenia, drug reaction, and 
other. Neutropenic fever and infection were collapsed into one category and anemia and 
thrombocytopenia were collapsed into another category due to the overlap in discharge 
diagnoses descriptors. The “other” category included reasons such as a fall, cholecystitis, 
and optic neuropathy.
The most common reasons for all visits were neutropenic fever/infection (56%), bleeding 
(12%), and GI problems (10%). For both AML and ALL patients, the most common event 
reason was neutropenic fever/infection, but it was higher for AML compared to ALL (62% v 
49%, p<0.0001). The reasons for the other AML events were 7% bleeding and 10% 
respiratory, compared to the ALL patients who had 12% GI issues and 11% bleeding events. 
[Table 3].
Number of Events—No significant differences were seen in the number of events based 
on gender, minority, marital status, or being in remission at discharge (Table 4). However, in 
univariable analysis, the variables that showed associations were: disease status (p= 0.002), 
insurance (p= 0.06), and age had more events (p= 0.001). The mean number of events for 
ALL patients was 2.43 compared to 1.33 for AML patients, 2.05 for private insurance 
compared to 1.42 for those with government insurance, and 2.23 for those under 50 years 
old compared to 1.20 for those older. In a multivariable model for the outcome of number of 
events, leukemia type and age retained their significant associations with number of events 
(p=0.006, 0.017), respectively. On average, patients with ALL had 1 more event than those 
with AML, and the number of events decreased by 0.24 for each 10 year increase in age.
Time to First Event—Time from discharge to first event was estimated for the entire 
group and found to be 72 days (95%CI: 47–115). In univariable analysis, only age and 
leukemia type showed significant associations with time to event (p=0.001, 0.01, 
respectively, Table 5). The median time to event was 44 days for those younger than 50 
compared to 115 for those older and 36.5 days for ALL patients compared to 115 for ALL 
patients. No other characteristics showed differences. In a multivariable model leukemia 
type and age retained their significant association with time to first event. After controlling 
for other covariates, the HR for each 10 unit increase in age is 0.76 indicating fewer ED 
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visits and hospitalizations occurred in older patients. From the same multivariable model, 
the HR for ALL v AML was 1.8 indicating more ED visits and hospitalizations with that 
type of leukemia.
Discussion
This retrospective chart review showed that 81% of patients discharged from initial 
induction treatment for acute leukemia had an unplanned visit to the ED or hospital within 
the first year. Younger age and having ALL made patients more likely to have an unplanned 
visit, even after controlling for gender, minority status, insurance, and remission status. The 
top reason for these visits were neutropenic fever/ infection, bleeding and GI problems. This 
is the first study, to our knowledge, to explore reasons for ED and hospital utilization by 
adults with acute leukemia after induction therapy.
It is not surprising that patients treated for acute leukemia were admitted for neutropenic 
fever/infection. A fever is often the first clinical sign of infection or a manifestation of the 
leukemic process and patients are counseled to seek medical attention when first developing 
a fever (Raab et al, 1960; Flowers et al, 2013). Evidence based guidelines support early, 
empirical broad-spectrum antibiotic therapy within 1 hour after blood cultures have been 
obtained when a neutropenic patient presents with a fever of 100.4 or higher (Eastman, 
2013). Some of these patients had central line associated bloodstream infection (CLABSI) 
which led to them being hospitalized due to local or systemic symptoms. Bryant et al (2014) 
presented a case study on a younger ALL male who entered the ED with febrile neutropenia. 
This case study provides appropriate, evidence based instructions for care of acute leukemia 
patients who enter the ED with febrile neutropenia. A quick, but thorough assessment is 
essential to improve the outcomes for a patient with neutropenic fever or an infection.
Bleeding was the 2nd most common reason (12% of visits) for care that requires immediate 
medical attention, and, along with thrombosis, is a significant risk factor for early mortality 
in patients with acute leukemia (Rickles et al 2007). Patients with acute leukemia are at a 
high risk for bleeding, including hemorrhage, and preventive measures can reduce this risk 
(Pereira & Phan, 2004). Bleeding can occur for a variety of reasons, one being low platelet 
count. Oncology providers must educate the patient and caregivers on earlier identification 
and recognition of bleeding. Creedle et al (2012) support standardized patient education can 
improve health outcomes for the patient and caregiver.
Gastrointestinal issues such as nausea, vomiting, and dehydration were the 3rd most common 
reason (10% of visits) for care, particularly patients with ALL. Early recognition of GI 
issues may decrease the number of ED visits which may be successfully treated as an 
outpatient. Vandyk et al (2012) systematic review reported fever, infection, pain, and 
respiratory distress were common symptoms identified when patients with cancer entered 
the ED. The urgency for all care services was warranted and was deemed clinically 
important.
Multivariable modeling identified those patients with ALL as using health services more 
frequently, which was unexpected. Future research exploring why these patient 
Bryant et al. Page 6













characteristics had higher use of services is needed. These patients may warrant further 
monitoring by patient navigators, follow-up calls, and more frequent clinic visits. 
Additionally, increasing patient age was associated with fewer events; for each 10 year 
increase in age the average number of events decreased by 0.24. This finding may be 
associated with the ALL sample who were more likely to be younger, sicker, and with a 
shorter time from diagnosis to their first event. Our findings using Donabedian’s framework 
supported the idea that when patients with acute leukemia enter the ED or hospital 
(structure), their diagnoses are accurately made and appropriately treated (process), resulting 
in an ED discharge or admission to the hospital for further evaluation (outcome).
Our study is limited by having been conducted at a single institution and retrospectively 
collecting data from medical charts. We were unable to collect data on other health services 
used by these patients outside of this one setting. We saw that patients were returning for 
visits with their physician, and thus it is reasonable to assume that the physician would have 
commented on ED or hospitalization visits in their notes. We did not capture type of 
induction therapy which may impact frequency and use of services. Despite limitations, this 
study highlights ED visits and hospitalization use in the acute leukemia population, which 
spans from young adulthood to older adult ages.
In conclusion, our study builds upon previous preliminary work exploring ED visits by 
patients with cancer (Mayer et al, 2011). We were able to follow these patients from the time 
of discharge from induction for a full year after and demonstrated that younger age and 
having ALL contributed to having more unplanned visits to the ED and hospital. With an 
81% unplanned visit to the ED or hospital within the first year, there are patients at risk for 
services, and others at higher risk.
This information can help providers identify a higher-risk population for symptom 
management, and also assist oncology providers in anticipating discharge needs and support 
follow-up care for those at greater risk for ED and hospital utilization after induction 
treatment for acute leukemia. Future research linking health claims databases might provide 
a more comprehensive picture of additional services (ie. home health, hospice) utilized by 
these patients across their acute leukemia trajectory. Future research that focuses on 
improving the management of the identified symptoms can help to optimize quality of life 
and care for these patients.
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• 81% of patients had an unplanned visit to the ED or hospital within the first 
year.
• Top reasons for visits were neutropenic fever/ infection, bleeding and 
gastrointestinal problems.
• Those with ALL were younger, sicker, and had shorter time from diagnosis to 
1st event compared to those with AML
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Eligibility of Patients Newly Diagnosed with Acute Leukemia between 2007–2010
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Table 2








In Remission 56 (70%) 34 (65%) 22 (79%)
0.31Not in remission 24 (30%) 18 (35%) 6 (21%)
Number of Events
0 15 (19%) 13 (25%) 2 (7%)
0.05
1 30 (38%) 21 (40%) 9 (32%)
2 14 (18%) 9 (17%) 5 (18%)
>3 21 (27%) 9 (17%) 12 (43%)
Time to 1st Event
(median, 95%
CI)
72 (47–115) 115 (63–154) 36.5 (26–66) 0.005
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Table 3







Neutropenic fever/infection 76 (56%) 43 (62%) 33 (49%)
Anemia/thrombocytopenia 16 (12%) 5 (7%) 11 (16%)
Gastrointestinal 14 (10%) 2 (3%) 12 (18%)
Respiratory 10 (7%) 7 (10%) 3 (4%)
Pain 7 (5%) 4 (6%) 3 (4%)
Cardiovascular 4 (3%) 2 (3%) 2 (3%)
Drug Reaction 2 (2%) 2 (3%) 0 (0%)
Other 8 (6%) 4 (6%) 4 (6%)
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Table 4
Linear Regression Model for Number of Events
Variables Univariable Multivariable
Estimate p-value Estimate p-value
Gender (male) −.083 .81 − −
Minority −.16 .68 −.57 .11
Not married .32 .41 − −
Government
Insurance
−.64 .06 −.47 .14
ALL 1.1 .002 .99 .006
In remission −.17 .64 −.45 .19
Age Diagnosis
(10 years)
−.30 .001 −.24 .017













Bryant et al. Page 17
Table 5
Cox Proportional Hazard Model for Time to First Event
Variables Univariable Multivariable
Hazard Ratio p-value Hazard Ratio p-value
Gender (male) 1.18 .51 − −
Minority 1.08 .78 .90 .72
Not married 1.25 .44 − −
Government
Insurance
0.63 .07 .79 .37
ALL 2.02 .01 1.8 .03
In remission 1.03 .93 0.78 .41
Age Diagnosis
(10 years)
0.75 .001 0.76 .004
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